Stephan Buch
Overview
Explore the profile of Stephan Buch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
2852
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galvanin C, Buch S, Nahon P, Trepo E
Liver Int
. 2024 Dec;
45(1):e16211.
PMID: 39679853
The discovery of PNPLA3 as a genetic risk factor for liver disease has transformed our understanding of the pathogenesis of alcohol-related liver disease (ALD). The recent reclassification of fatty liver...
2.
Innes H, Buch S, Kendall T, Fallowfield J, Guha I
Liver Int
. 2024 Oct;
44(12):3260-3273.
PMID: 39425533
Background And Aims: Individuals with genetic polymorphisms in UGT1A1 exhibit bilirubin levels that belie their risk of liver disease (Gilbert's syndrome) but it is not known if this phenomenon extends...
3.
Innes H, Morgan M, Hampe J, Stickel F, Buch S
Aliment Pharmacol Ther
. 2023 Jul;
58(6):623-631.
PMID: 37470344
Background: The influence of genetic factors on survival following a diagnosis of hepatocellular carcinoma (HCC) remains unclear. Aim: To assess whether genetic polymorphisms influencing the susceptibility to develop HCC are...
4.
Schmalz F, Fischer J, Innes H, Buch S, Moller C, Matz-Soja M, et al.
JHEP Rep
. 2023 Mar;
5(4):100684.
PMID: 36879887
Background & Aims: Progression of alcohol-associated liver disease (ALD) is driven by genetic predisposition. The rs13702 variant in the lipoprotein lipase (LPL) gene is linked to non-alcoholic fatty liver disease....
5.
Nischalke H, Schmalz F, Buch S, Fischer J, Moller C, Matz-Soja M, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499681
Hepatocellular carcinoma (HCC) is a severe complication of advanced alcoholic liver disease, which is modulated by genetic predisposition. Identifying new genetic loci might improve screening. Genetic variation of SAMM50 was...
6.
Buch S, Innes H, Lutz P, Nischalke H, Marquardt J, Fischer J, et al.
Gut
. 2022 Jul;
72(2):381-391.
PMID: 35788059
Objective: Hepatocellular carcinoma (HCC) often develops in patients with alcohol-related cirrhosis at an annual risk of up to 2.5%. Some host genetic risk factors have been identified but do not...
7.
Innes H, Morling J, Buch S, Hamill V, Stickel F, Guha I
J Hepatol
. 2022 Mar;
77(2):365-376.
PMID: 35271950
Background & Aims: Models predicting an individual's 10-year risk of cirrhosis complications have not been developed for a community setting. Our objectives were to assess the performance of existing risk...
8.
Mancina R, Sasidharan K, Lindblom A, Wei Y, Ciociola E, Jamialahmadi O, et al.
Nat Metab
. 2022 Feb;
4(1):60-75.
PMID: 35102341
Fatty liver disease (FLD) is a growing health issue with burdening unmet clinical needs. FLD has a genetic component but, despite the common variants already identified, there is still a...
9.
Innes H, Nischalke H, Guha I, Weiss K, Irving W, Gotthardt D, et al.
Hepatol Commun
. 2021 Dec;
6(5):1213-1226.
PMID: 34958182
The host genetic background for hepatocellular carcinoma (HCC) is incompletely understood. We aimed to determine if four germline genetic polymorphisms, rs429358 in apolipoprotein E (APOE), rs2642438 in mitochondrial amidoxime reducing...
10.
Vvedenskaya O, Rose T, Knittelfelder O, Palladini A, Wodke J, Schuhmann K, et al.
J Lipid Res
. 2021 Aug;
62:100104.
PMID: 34384788
Nonalcoholic fatty liver disease (NAFLD) is a common metabolic dysfunction leading to hepatic steatosis. However, NAFLD's global impact on the liver lipidome is poorly understood. Using high-resolution shotgun mass spectrometry,...